Ranbaxy Laboratories

Ranbaxy Laboratories Limited, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is headquartered in India. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world’s emerging and developed markets.

Ranbaxy Laboratories Limited was incorporated in 1961. The CEO of the company is Malvinder Mohan Singh. The company was made public in 1973. Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. In 1998, Ranbaxy entered the United States of America, the world’s largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy’s sales.

The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the acute segment.

Most of Ranbaxy’s products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.

The Company has successfully pursued its inorganic growth strategy and concluded over 15 acquisitions since 2004, including the latest 9 acquisitions valued at US$ 450 Mn (4 in Europe, 1 in the US, 3 in India and 1 in South Africa). These acquisitions have significantly expanded its business in emerging and profitable markets. The Company will continue to evaluate acquisition options in US, Europe, India and emerging markets to accentuate its business and competitiveness in these markets.

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The Company today has a pool of 1,200 scientists who are engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70’s. To support its global ambition a first of its kind world class R&D centre was commissioned in 1994. Today, the Company’s multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Company’s robust R&D environment for both drug discovery & development reflects the Company’s commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

The company’s NDDS focus is mainly on the development of NDA/ ANDAs of oral controlled- release products for the regulated markets. The Company’s first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.

The research areas for drug discovery at Ranbaxy are anti-infectives, inflammatory / respiratory, metabolic diseases and Oncology. Presently, the Company has 10 programs in the area of NDDR including one NCE in Phase-II clinical trials. The Company has received approvals to commence Phase I studies in India on its NCE molecule for Dyslipidemia. In addition, the Company also has a number of other pre-clinical leads in various segments.

Ranbaxy also has a global alliance in the area of drug discovery and development with GlaxoSmithKline Plc. Presently two research programs have been initiated under this alliance. Leadership in Novel Drug Delivery System (NDDS) products, which offer value-added differentiation over conventional products. Key brands include Cifran OD (Ciprofloxacin), Zanocin OD (Ofloxacin) & Sporidex AF (Cephalexin). Strong brand building capabilities, reflected in the fact that 20 brands feature in the “Top-300 brands of the Industry” list. The leading 5 brands are Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxicillin), Zanocin (Ofloxacin) & Volini (Diclofenac).

Great emphasis is placed on Knowledge Management and Medico-marketing initiatives such as Advisory Board Meetings, Post Marketing Surveillance Studies and Continuous Medical Education programs. These have resulted in an excellent customer relationship with the medical fraternity. More than 2000 interface programs (Symposia, CME’s) are conducted and about 20 Clinical Papers published annually.

Dry Power & Metered Dose Inhalers have been launched in the Respiratory segment. All Metered Dose Inhalers are HFA based formulations, environment friendly inhalers. It is for the first time in India, that a company has launched its entire HFA propellant based MDI range. The world’s first novel product, Osovair (Formoterol + Ciclesonide) inhalation capsules has been introduced in the Indian market.

Driven by the passion of its over 11,000 strong multicultural workforce comprising 51 nationalities, Ranbaxy continues to aggressively pursue its mission to become a Research-based International Pharmaceutical Company and attain a true global leadership position.